Document:

EX-4.5

 Exhibit 4.5 

NINTH SUPPLEMENTAL INDENTURE dated as of January 26, 2015, among Covidien International Finance S.A., a Luxembourg company (the
“Company”), Covidien Ltd., a Bermuda company (“CLTD”), Covidien plc, a public limited company incorporated under the laws of Ireland (“CPLC” and, together with CLTD, the “Current
Guarantors”), Medtronic plc, a public limited company incorporated under the laws of Ireland (“New Medtronic”), Medtronic Global Holdings SCA, a corporate partnership limited by shares (société en
commandite par actions) organized under the laws of the Grand Duchy of Luxembourg (“Medtronic Luxco” and, together with New Medtronic, the “Parent Guarantors”) and Deutsche Bank Trust Company Americas, a New
York banking corporation, as trustee (the “Trustee”). 
 W I T N E S S E T H 

WHEREAS, the Company and CLTD have heretofore executed and delivered to the Trustee an Indenture, dated as of October 22, 2007 (the
“Original Base Indenture” and, as subsequently amended by the Fifth Supplemental Indenture, the “Base Indenture”), providing for the issuance from time to time of the Company’s debentures, notes or other
evidences of indebtedness (herein and therein called the “Securities”), to be issued in one or more series as provided in the Base Indenture, and for the issuance of guarantees of the Securities; 

WHEREAS, the Company and CLTD have heretofore executed and delivered to the Trustee a first supplemental indenture dated as of
October 22, 2007 (the “First Supplemental Indenture”), providing for the issuance of $250,000,000 aggregate principal amount of 5.150% senior notes due 2010 (the “First Notes”); 

WHEREAS, the Company and CLTD have heretofore executed and delivered to the Trustee a second supplemental indenture dated as of
October 22, 2007 (the “Second Supplemental Indenture”), providing for the issuance of $500,000,000 aggregate principal amount of 5.450% senior notes due 2012 (the “Second Notes”); 

WHEREAS, the Company and CLTD have heretofore executed and delivered to the Trustee a third supplemental indenture dated as of
October 22, 2007 (the “Third Supplemental Indenture”), providing for the issuance of $1,150,000,000 aggregate principal amount of 6.000% senior notes due 2017 (the “Third Notes”); 

WHEREAS, the Company and CLTD have heretofore executed and delivered to the Trustee a fourth supplemental indenture dated as of
October 22, 2007 (the “Fourth Supplemental Indenture”), providing for the issuance of $850,000,000 aggregate principal amount of 6.550% senior notes due 2037 (the “Fourth Notes”) 

WHEREAS, the Company, CLTD and CPLC have heretofore executed and delivered to the Trustee a fifth supplemental indenture dated as of
June 4, 2009 (the “Fifth Supplemental Indenture”), providing for the addition of CPLC as an additional guarantor under the Base Indenture and the Securities, including the First Notes, the Second Notes, the Third Notes and the
Fourth Notes, and to make certain other amendments; 
 WHEREAS, the Company and the Current Guarantors have heretofore executed and
delivered to the Trustee a sixth supplemental indenture dated as of June 28, 2010 (the “Sixth Supplemental Indenture”), providing for the issuance of $500,000,000 aggregate principal amount of 1.875% senior notes due 2013,
$400,000,000 aggregate principal amount of 2.80% senior notes due 2015 and $600,000,000 aggregate principal amount of 4.20% senior notes due 2020 (collectively, the “Fifth Notes”); 

 WHEREAS, the Company and the Current Guarantors have heretofore executed and delivered to the
Trustee a seventh supplemental indenture dated as of May 30, 2012 (the “Seventh Supplemental Indenture”), providing for the issuance of $600,000,000 aggregate principal amount of 1.350% senior notes due 2015 and $650,000,000
aggregate principal amount of 3.200% senior notes due 2022 (collectively, the “Sixth Notes”); 
 WHEREAS, the Company and
the Current Guarantors have heretofore executed and delivered to the Trustee an eighth supplemental indenture dated as of May 16, 2013 (the “Eighth Supplemental Indenture” and, together with the First Supplemental Indenture,
the Second Supplemental Indenture, the Third Supplemental Indenture, the Fourth Supplemental Indenture, the Fifth Supplemental Indenture, the Sixth Supplemental Indenture and the Seventh Supplemental Indenture, the “Indenture”),
providing for the issuance of $750,000,000 aggregate principal amount of 2.950% senior notes due 2023 (the “Seventh Notes” and, together with the First Notes, the Second Notes, the Third Notes, the Fourth Notes, the Fifth Notes and
the Sixth Notes, the “Notes”); 
 WHEREAS, Section 9.01(h) of the Base Indenture permits the Company, the Current
Guarantors and the Trustee, without the consent of any Securityholder, to enter into an indenture supplemental to the Base Indenture to make any change that does not adversely affect the rights of any Securityholder of Outstanding Securities in any
material respect; 
 WHEREAS, pursuant to Section 9.01 of the Base Indenture, the Trustee is authorized to execute and deliver this
Ninth Supplemental Indenture. 
 NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the
receipt of which is hereby acknowledged, the parties mutually covenant and agree for the equal and ratable benefit of the Securityholders as follows: 

SECTION 1. Capitalized Terms. Capitalized terms used herein without definition shall have the meanings assigned to them in the Base
Indenture and the rules of construction contained in the Base Indenture will apply equally to this Ninth Supplemental Indenture. 
 SECTION
2. Definitions. For all purposes of this Ninth Supplemental Indenture, the terms defined in this Section 2 have the meanings assigned to them in this Section: 

“Parent Guaranty” means a guarantee by a Parent Guarantor pursuant to Section 3 of this Ninth Supplemental Indenture.

 “Other Guarantor” means any guarantor, other than a Parent Guarantor, of the Indenture and
the Notes. 
 SECTION 3. Parent Guarantee. 

(a) Each Parent Guarantor, hereby, jointly and severally, irrevocably and unconditionally guarantees, on a senior basis, for itself and its
successors and assigns, irrespective of the validity and enforceability of the Indenture or the Notes, or the obligations of the Company thereunder, that: (1) the principal of and premium, if any, and interest on the Notes, shall be promptly
paid in full when due, whether at maturity, by acceleration, redemption or otherwise, and interest on the overdue principal of and interest on the Notes, if any, if lawful, shall be promptly paid in full, all in accordance with the terms of the
Indenture and the Notes; and (2) in case of any extension of time of payment of renewal of any Notes, that same shall be promptly paid in full when due in accordance with the terms of the extension or renewal, whether a stated maturity, by
acceleration or otherwise. Failing payment by the Company when due of any amount so guaranteed for whatever reason, the Parent Guarantors shall be jointly and severally obligated to pay the same immediately. Each Parent Guarantor agrees that this is
a guarantee of payment and not a guarantee of collection. 

 (b) The Parent Guarantors hereby agree that their obligations under the Indenture and the Notes
shall be unconditional, irrespective of the validity, regulatory or enforceability of the Indenture or the Notes, the absence of any action to enforce the same, any waiver or consent by any Securityholder with respect to any provisions of the
Indenture or the Notes, the recovery of any judgment against the Company, any action to enforce the same or any other circumstance which might otherwise constitute a legal or equitable discharge or defense of a guarantor. Each Parent Guarantor
hereby waives diligence, presentment, demand of payment, filing of claims with a court in the event of insolvency or bankruptcy of the Company, any right to require a proceeding first against the Company, protest, notice and all demands whatsoever
and covenants that a Parent Guaranty shall not be discharged except by complete performance of the obligations contained in the Indenture and the Notes, or pursuant to Section 3(c) of this Ninth Supplemental Indenture. 

(c) A Parent Guaranty by a Parent Guarantor shall be automatically and unconditionally released and discharged, and such Parent Guaranty shall
thereupon terminate and be discharged and be of no further force and effect, and no further action by such Parent Guarantor, the Company or the Trustee shall be required for the release of such Parent Guarantor’s Parent Guaranty: (A) upon
the merger or consolidation of such Parent Guarantor with and into the Company, any other Parent Guarantor or any Other Guarantor that is a surviving person in such merger or consolidation, or upon the liquidation of such Parent Guarantor following
or concurrently with the transfer of all or substantially all of its assets to Company, another Parent Guarantor or any Other Guarantor (and, if applicable, any minority stockholders of such Parent Guarantor or Other Guarantor) or (B) upon the
Company exercising its legal defeasance or covenant defeasance options in accordance with the terms of the Indenture and the Notes. 

SECTION 4. Each Parent Guarantor acknowledges that it will receive direct and indirect benefits from the financing arrangements contemplated
by its Parent Guaranty, the Indenture and this Ninth Supplemental Indenture and that the guarantee and waivers made by it pursuant to its Parent Guaranty are knowingly made in contemplation of such benefits. 

SECTION 5. No past, present or future stockholder, officer, director, employee or incorporator of any Parent Guarantor shall have any
liability under the Parent Guaranty, the Indenture or this Ninth Supplemental Indenture by reason of such person’s status as stockholder, officer, director, employee or incorporator. 

SECTION 6. Relationship to Existing Base Indenture. This Ninth Supplemental Indenture is a supplemental indenture within the meaning of
the Base Indenture. The Base Indenture, as amended and supplemented by this Ninth Supplemental Indenture, is in all respects ratified, confirmed and approved and, with respect to the Notes, the Base Indenture, as amended and supplemented by this
Ninth Supplemental Indenture, shall be read, taken and construed as one and the same instrument. 
 SECTION 7. Governing Law. THIS
NINTH SUPPLEMENTAL INDENTURE WILL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK AND OF THE UNITED STATES. 

SECTION 8. Waiver of Jury Trial. EACH OF THE COMPANY, THE CURRENT GUARANTORS AND THE PARENT GUARANTORS AND THE TRUSTEE HEREBY
IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS NINTH SUPPLEMENTAL INDENTURE, ANY PARENT GUARANTY OR THE TRANSACTION CONTEMPLATED
HEREBY. 

 SECTION 9. Headings. The headings of the Sections of this Ninth Supplemental
Indenture have been inserted for convenience of reference only, are not to be considered a part of this Ninth Supplemental Indenture and shall in no way modify or restrict any of the terms or provisions hereof. 

SECTION 10. Counterparts. The parties may sign any number of copies of this Ninth Supplemental Indenture. Each signed copy shall be an
original, but all of them together represent the same agreement. The exchange of copies of this Ninth Supplemental Indenture and of signature pages by facsimile or .pdf transmission shall constitute effective execution and delivery of this Ninth
Supplemental Indenture as to the parties hereto and may be used in lieu of the original Ninth Supplemental Indenture for all purposes. Signatures of the parties hereto transmitted by facsimile or .pdf shall be deemed to be their original signatures
for all purposes. 
 SECTION 11. Trustee. The Trustee shall not be responsible in any manner whatsoever for or in the respect of the
validity or sufficiency of this Ninth Supplemental Indenture or for or in respect of the recitals contained herein, all of which recitals are made solely by the Company, the Current Guarantors and the Parent Guarantors, as the case may be. 

[Signature Page Follows] 

 IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly executed, all as of the
date first above written. 
  

					
	COVIDIEN INTERNATIONAL FINANCE S.A.
		
	By:		 /s/ Philip J. Albert

			Name:		Philip J. Albert
			Title:		Chairman of the Board

 [Supplemental Indenture Signature Page] 

 IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly executed, all as of the
date first above written. 
  

					
	COVIDIEN PUBLIC LIMITED COMPANY
		
	By:		 /s/ Gary L. Ellis

			Name:		Gary L. Ellis
			Title:		President and Chief Financial Officer

 [Supplemental Indenture Signature Page] 

 IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly executed, all as of the
date first above written. 
  

					
	COVIDIEN LTD.
		
	By:		 /s/ Gary L. Ellis

			Name:		Gary L. Ellis
			Title:		President and Chief Financial Officer

 [Supplemental Indenture Signature Page] 

 IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly executed, all as of the
date first above written. 
  

					
	 SIGNED AND DELIVERED as a Deed
 for and
on behalf of
				
	 MEDTRONIC PLC
 by its lawfully appointed
attorney
				
	 GARY L. ELLIS
 in the presence
of:
				
			
					 /s/ Gary L. Ellis

	 /s/ Althea Laska
				Signature of Attorney
	(Witness’ Signature)				
			
	 Althea Laska
				
	(Witness’ Name)				
			
	 710 Medtronic Parkway, Minneapolis, Minnesota
				
	(Witness’ Address)				
			
	 Exec. Assistant
				
	(Witness’ Occupation)				

 [Supplemental Indenture Signature Page] 

 IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly executed, all as of the
date first above written. 
 MEDTRONIC GLOBAL HOLDINGS S.C.A., 

as Guarantor 
 a Luxembourg corporate partnership limited by
shares (société en commandite par actions) 
 represented by 

Medtronic Global Holdings GP S.à r.l. 
 Its General
Partner, in turn acting by 
  

					
	 By:
		 /s/ Andrej Grossmann

			Name:		Andrej Grossmann
			Title:		Class A Manager
	
	AND
		
	By:		 /s/ Linda Harty

			Name:		Linda Harty
			Title:		Class B Manager

 IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly executed, all as of the
date first above written. 
  

			
	DEUTSCHE BANK TRUST COMPANY AMERICAS, as Trustee
		
	By:		 /s/ Carol Ng

	Name:		Carol Ng
	Title:		Vice President
		
	By:		 /s/ Anthony D’Amato

	Name:		Anthony D’Amato
	Title:		AssociateEX-4.6

 Exhibit 4.6 

Execution Version 

REGISTRATION RIGHTS JOINDER AGREEMENT 

JANUARY 26, 2015 
 WHEREAS,
Medtronic, Inc., a Minnesota corporation (the “Company”) and the Representatives of the several Initial Purchasers named therein (the “Representatives”) heretofore executed and delivered a Purchase Agreement, dated
December 1, 2014 (the “Purchase Agreement”), providing for the issuance and sale of the Securities; and 
 WHEREAS, in
connection with the Purchase Agreement, the Company and the Representatives heretofore executed and delivered a Registration Rights Agreement, dated December 10, 2014 (the “Registration Rights Agreement”), pursuant to which the
Company agreed to file a registration statement with the Commission registering an exchange offer for the Securities and/or the resale of the Securities under the Securities Act; and 

WHEREAS, neither Medtronic public limited company, an Irish public limited company (“New Medtronic”), nor Medtronic Global Holdings,
S.C.A., a Luxembourg corporate partnership limited by shares (société en commandite par actions) (“Medtronic Luxco”) was originally a party thereto, but each has agreed to join in the Registration Rights Agreement (the
“Registration Rights Agreement”). 
 Capitalized terms used herein and not otherwise defined herein shall have the meanings
ascribed to such terms in the Purchase Agreement and the Registration Rights Agreement. 
 NOW, THEREFORE, each of New Medtronic and
Medtronic Luxco hereby agrees for the benefit of the Representatives, as follows: 
 1. Joinder. Each of the undersigned hereby
acknowledges that it has received and reviewed a copy of the Registration Rights Agreement and all other documents it deems fit in order to enter into this Registration Rights Joinder Agreement (the “Registration Rights Joinder
Agreement”), and acknowledges and agrees unconditionally and irrevocably (i) to join and become a party to the Registration Rights Agreement as indicated by its signature below as of the date hereof and shall have the same rights and
obligations thereunder as if it had been an original signatory to the Registration Rights Agreement; (ii) to be bound by all representations, warranties, agreements and obligations attributable to a Guarantor in the Registration Rights
Agreement as if made by, and with respect to, such undersigned in accordance with the terms of the Registration Rights Agreement as of the date hereof; and (iii) to perform all obligations and duties required of a Guarantor pursuant to the
Registration Rights Agreement. 
 2. Representations and Warranties and Agreements of each Guarantor. Each of the undersigned hereby
represents and warrants to and agrees with the Representatives that it has all requisite corporate power and authority to execute, 

 
deliver and perform its obligations under this Registration Rights Joinder Agreement and it has duly and validly taken all necessary action for the consummation of the transactions contemplated
hereby and by the Registration Rights Agreement and that it has duly authorized, executed and delivered this Registration Rights Joinder Agreement and it is a valid and legally binding agreement enforceable against such undersigned in accordance
with its terms. 
 3. Counterparts. This Registration Rights Joinder Agreement may be signed in one or more counterparts (which may be
delivered in original form or a facsimile or “pdf” file thereof), each of which shall constitute an original when so executed and all of which together shall constitute one and the same agreement. 

4. Amendments. No amendment or waiver of any provision of this Registration Rights Joinder Agreement, nor any consent or approval to any
departure therefrom, shall in any event be effective unless the same shall be in writing and signed by the parties thereto. 
 5.
Headings. The section headings used herein are for convenience only and shall not affect the construction hereof. 
 6.
Severability of Provisions. If any term or other provision of this Registration Rights Joinder Agreement is invalid, illegal or incapable of being enforced by any rule of law, or public policy, all other provisions of this Registration Rights
Joinder Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the agreements contained herein is not affected in any manner adverse to any party. Upon such determination that any term or provision
is invalid, illegal or unenforceable, the parties hereto shall negotiate in good faith to modify this Registration Rights Joinder Agreement so as to effect the original intent of the parties as closely as possible in a mutually acceptable manner in
order that the agreements contained herein may be performed as originally contemplated to the fullest extent possible. 
 7. Applicable
Law. This Registration Rights Joinder Agreement and any claim, controversy or dispute arising under or related to this Registration Rights Joinder Agreement shall be governed by, and construed in accordance with, the laws of the State of New
York. 
 8. Submission to Jurisdiction. Each of New Medtronic and Medtronic Luxco hereby submits to the exclusive jurisdiction of the
U.S. federal and New York state courts in the Borough of Manhattan in The City of New York in any suit or proceeding arising out of or relating to this Registration Rights Joinder Agreement or the transactions contemplated hereby. Each of New
Medtronic and Medtronic Luxco waives any objection which it may now or hereafter have to the laying of venue of any such suit or proceeding in such courts. Each of New Medtronic and Medtronic Luxco agrees that final judgment in any such suit, action
or proceeding brought in such court shall be conclusive and binding upon it and may be enforced in any court to the 

  
 2 

 
jurisdiction of which it is subject by a suit upon such judgment. New Medtronic irrevocably designates and appoints C T Corporation System, having an office on the date hereof at 111 Eighth
Avenue, New York, New York, and Medtronic Luxco irrevocably designates and appoints C T Corporation System, having an office on the date hereof at 111 Eighth Avenue, New York, New York, as its respective authorized agent upon which process may be
served in any such suit or proceeding (each, an “Authorized Agent”). Each of New Medtronic and Medtronic Luxco agrees that service of process upon such Authorized Agent, and written notice of such service to it at the address set forth
below, shall be deemed in every respect effective service of process upon New Medtronic or Medtronic Luxco, as applicable, in any such suit or proceeding. 

New Medtronic: 
 Medtronic plc

 20 Lower Hatch Street 

Dublin 2, Ireland 
 Attention:
General Counsel 
 with a copy (which shall not constitute notice to New Medtronic) to: 

Medtronic, Inc. 
 710 Medtronic
Parkway 
 Minneapolis, Minnesota 55432-5604 

Attention: Treasury Department, Mail Stop LC480 

Facsimile: (763) 505-2700 

E-mail: rs.corporatetreasury@medtronic.com 

Medtronic Luxco: 
 Medtronic
Global Holdings, S.C.A. 
 1, rue du Potager 

L-2347, Luxembourg, Grand Duchy of Luxembourg 

Attention: General Partner 

Facsimile: +352 24 611714 
 with a
copy (which shall not constitute notice to Medtronic Luxco) to: 
 Medtronic, Inc. 

710 Medtronic Parkway 

Minneapolis, Minnesota 55432-5604 

Attention: Treasury Department, Mail Stop LC480 

Facsimile: (763) 505-2700 

E-mail: rs.corporatetreasury@medtronic.com 

Each of New Medtronic or Medtronic Luxco hereby represents and warrants that such Authorized Agent has accepted such appointment and has
agreed to act as such authorized agent (or another such agent satisfactory to the Representatives) for service of process. 
 [Signature page
follows] 

  
 3 

 IN WITNESS WHEREOF, the undersigned have executed this Registration Rights Joinder Agreement as
of the date first written above. 
  

			
	MEDTRONIC PLC
		
	By:		 /s/ Gary L. Ellis

			Name: Gary L. Ellis
			Title: Lawfully appointed attorney
	
	 MEDTRONIC GLOBAL HOLDINGS S.C.A.a Luxembourg corporate partnership limited by shares (société en commandite par
actions) represented by Medtronic Global Holdings GP S.à r.l.
 Its General Partner, in turn acting by

		
	By:		 /s/ Andrej Grossmann

			Name: Andrej Grossmann
			Title: Class A Manager
	
	AND
		
	By:		 /s/ Linda Harty

			Name: Linda Harty
			Title: Class B Manager

 The foregoing Registration Rights Joinder Agreement is hereby confirmed and accepted by the Initial Purchasers as
of the date first written above. 
  

			
	 MERRILL LYNCH, PIERCE, FENNER & SMITH

INCORPORATED

	
	DEUTSCHE BANK SECURITIES INC.
	
	J.P. MORGAN SECURITIES LLC
	
	For themselves and on behalf of the several Initial Purchasers listed in Schedule 1 hereto.
	
	 By: MERRILL LYNCH, PIERCE, FENNER & SMITH

INCORPORATED

		
	By		 /s/ Douglas Muller

			Authorized Signatory
	
	By: DEUTSCHE BANK SECURITIES INC.
		
	By		 /s/ John Han

			Authorized Signatory
		
	By		 /s/ Anguel Zaprianov

			Authorized Signatory
	
	By: J.P. MORGAN SECURITIES LLC
		
	By		 /s/ Robert Bottamedi

			Authorized Signatory

 [Registration Rights Joinder Agreement Signature Page]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}]]